Alexion Pharmaceuticals Inc., of New Haven, Conn., promoted Stephen Squinto to executive vice president and head of research; Christopher Mojcik to vice president, clinical development; and Scott Rollins to vice president, drug development and project management. Also, Samuel Chu was named vice president, manufacturing and process sciences, and Louis Matis joined the scientific advisory board.

Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Tamar Howson to its board of directors. Howson is the former senior vice president and director, worldwide business development, at SmithKline Beecham.

Aviron, of Mountain View, Calif., named Harry Greenberg senior vice president, research and development, and chief scientific officer.

Axys Pharmaceuticals Inc., of South San Francisco, named Michael Green vice president of medicinal chemistry.

Cellomics Inc., of Pittsburgh, promoted William Busa to chief scientific officer and vice president for bioinformatics.

Collateral Therapeutics Inc., of San Diego, promoted John Warner to vice president of technology and research.

ExonHit Therapeutics SA, of Paris, named Florence Abrahamian financial director; Jim Liddy vice president, business development; and Aram Mangasarian director of business development.

Genetronics Biomedical Ltd., of San Diego, named Babak Nemati vice president of corporate development.

GenMatrix Inc., of Oakland, Calif., placed Martin Reese on its scientific advisory board.

Genomica Corp., of Boulder, Colo., appointed Sean Ryan vice president of sales.

Genteric Inc., of Alameda, Calif., appointed Roland Scollay vice president of research and chief scientific officer.

Iconix Pharmaceuticals Inc., of Mountain View, Calif., said Rudyard Istvan joined its board of directors.

Immunex Corp., of Seattle, named Kimberly Ives head of its finance department.

King Pharmaceuticals Inc., of Bristol, Tenn., named James Lattanzi chief financial officer.

KS Biomedix Holdings plc, of London, appointed Sally Waterman director of research and development.

Magainin Pharmaceuticals Inc., of Plymouth Meeting, Pa., said Michael Zasloff assumed the newly created position of scientific consultant.

Metabasis Therapeutics Inc., of San Diego, said Arnold Oronsky and Luke Evnin joined its board of directors.

Morphochem AG, of Munich, Germany, appointed Prabhavathi Fernandes to its scientific advisory board.

NeoTherapeutics Inc., of Irvine, Calif., appointed Martyn Gunning director of business development and licensing. It also promoted Samuel Gulko to senior vice president, finance, although he retains his positions as chief financial officer, secretary and treasurer. Alvin Glasky was appointed president of NeoGene Technologies Inc., the functional genomics subsidiary of NeoTherapeutics.

No Comments